# Alirocumab

## Praluent inj 75mg

| TAH Drug Code      | [IPRA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPRA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Hyperlipidemia, primary Secondary prevention of cardiovascular events                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Initial: 75 mg once every 2 weeks or 300 mg once every 4 weeks; for both regimens, if an adequate low-density lipoprotein cholesterol (LDL-C) response is not achieved, may increase or modify dosing regimen to a maximum of 150 mg every 2 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Serious hypersensitivity to alirocumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | >10%: Local: Injection-site reaction (children, adolescents, and adults: 4% to 17%; including erythema at injection site, injection-site pruritus, pain at injection site, swelling at injection site, tenderness at injection site) 1% to 10%: Gastrointestinal: Diarrhea (5%) Hepatic: Increased serum transaminases (>3 × ULN: 2%), liver enzyme disorder (3%) Hypersensitivity: Hypersensitivity reaction (9%; including hypersensitivity angiitis, nummular eczema) Immunologic: Antibody development (children and adolescents: 3%; adults: 6%; neutralizing: <1%) Infection: Influenza (6%) Neuromuscular & skeletal: Muscle spasm (3%), myalgia (4% to 6%) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/alirocumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

